US Stem Cell Inc (USRM)

[MyzStreet]

Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
* Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
* Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
* All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.

Per 10-k:
Today, we contend that U.S. Stem Cell is a combination of opportunistic business enterprises. We estimate that the products and services we offer through US Stem Cell Training, Vetbiologics, and US Stem Cell Clinics has the potential, although we cannot provide assurances as to if and when it will be accomplished, to drive up to $100 million dollars in cumulative peak annual revenues. What we are establishing is a foundation of value in the products and services we are selling and plan to sell from US Stem Cell Training, Vetbiologics, and US Stem Cell clinics. Our strategy is to expand the revenues generated from each of these operating divisions and to reinvest the profits we generate into our U.S. Stem Cell clinical development pipeline.